» Articles » PMID: 27829033

Outcomes of Nigeria's HIV/AIDS Treatment Program for Patients Initiated on Antiretroviral Treatment Between 2004-2012

Abstract

Background: The Nigerian Antiretroviral therapy (ART) program started in 2004 and now ranks among the largest in Africa. However, nationally representative data on outcomes have not been reported.

Methods: We evaluated retrospective cohort data from a nationally representative sample of adults aged ≥15 years who initiated ART during 2004 to 2012. Data were abstracted from 3,496 patient records at 35 sites selected using probability-proportional-to-size (PPS) sampling. Analyses were weighted and controlled for the complex survey design. The main outcome measures were mortality, loss to follow-up (LTFU), and retention (the proportion alive and on ART). Potential predictors of attrition were assessed using competing risk regression models.

Results: At ART initiation, 66.4 percent (%) were females, median age was 33 years, median weight 56 kg, median CD4 count 161 cells/mm3, and 47.1% had stage III/IV disease. The percentage of patients retained at 12, 24, 36 and 48 months was 81.2%, 74.4%, 67.2%, and 61.7%, respectively. Over 10,088 person-years of ART, mortality, LTFU, and overall attrition (mortality, LTFU, and treatment stop) rates were 1.1 (95% confidence interval (CI): 0.7-1.8), 12.3 (95%CI: 8.9-17.0), and 13.9 (95% CI: 10.4-18.5) per 100 person-years (py) respectively. Highest attrition rates of 55.4/100py were witnessed in the first 3 months on ART. Predictors of LTFU included: lower-than-secondary level education (reference: Tertiary), care in North-East and South-South regions (reference: North-Central), presence of moderate/severe anemia, symptomatic functional status, and baseline weight <45kg. Predictor of mortality was WHO stage higher than stage I. Male sex, severe anemia, and care in a small clinic were associated with both mortality and LTFU.

Conclusion: Moderate/Advanced HIV disease was predictive of attrition; earlier ART initiation could improve program outcomes. Retention interventions targeting men and those with lower levels of education are needed. Further research to understand geographic and clinic size variations with outcome is warranted.

Citing Articles

Retention in Care Among People Living with HIV in Nigeria: A Systematic Review and Meta-analysis.

Olawepo J, OBrien K, Papasodoro J, Coombs P, Singh N, Gupta S J Res Health Sci. 2024; 24(3):e00618.

PMID: 39311101 PMC: 11380731. DOI: 10.34172/jrhs.2024.153.


A Qualitative Study Exploring Factors Associated with Retention in HIV Care among Women with HIV in a Large HIV Clinic in Lagos, Nigeria, after Implementing the Test and Treat Policy.

Odediran O, Odukoya O, Balogun M, Colasanti J, Akanmu A AIDS Res Treat. 2022; 2022:9074844.

PMID: 35983188 PMC: 9381265. DOI: 10.1155/2022/9074844.


Analyses of Kaposi Sarcoma trends among adults establishing initial outpatient HIV care in Nigeria: 2006-2017.

Akanbi M, Bilaver L, Achenbach C, Hirschhorn L, Rivera A, Silas O Infect Agent Cancer. 2022; 17(1):10.

PMID: 35313941 PMC: 8935748. DOI: 10.1186/s13027-022-00424-4.


Patient and health facility attributes associated with retention and virologic suppression in private for-profit health facilities in Nigeria.

Aina M, Yesufu Z, Salisu A, Ezeanolue E, Mensah C, Dakum P AIDS Res Ther. 2022; 19(1):11.

PMID: 35193597 PMC: 8864871. DOI: 10.1186/s12981-022-00438-3.


Factors associated with an interruption in treatment of people living with HIV in USAID-supported states in Nigeria: a retrospective study from 2000-2020.

Tomescu S, Crompton T, Adebayo J, Kinge C, Akpan F, Rennick M BMC Public Health. 2021; 21(1):2194.

PMID: 34847909 PMC: 8638522. DOI: 10.1186/s12889-021-12264-9.


References
1.
Kaufmann G, Bloch M, Zaunders J, Smith D, Cooper D . Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy. AIDS. 2000; 14(8):959-69. DOI: 10.1097/00002030-200005260-00007. View

2.
Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, Labatala V . Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS. 2004; 18(6):887-95. DOI: 10.1097/00002030-200404090-00006. View

3.
Smith C, Sabin C, Youle M, Kinloch-De Loes S, Lampe F, Madge S . Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy. J Infect Dis. 2004; 190(10):1860-8. DOI: 10.1086/425075. View

4.
Bonnet F, Thiebaut R, Chene G, Neau D, Pellegrin J, Mercie P . Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002. HIV Med. 2005; 6(3):198-205. DOI: 10.1111/j.1468-1293.2005.00290.x. View

5.
Schaubel D . Variance estimation for clustered recurrent event data with a small number of clusters. Stat Med. 2005; 24(19):3037-51. DOI: 10.1002/sim.2157. View